Lixte Biotechnology Holdings Inc
General ticker "LIXT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.5M
Lixte Biotechnology Holdings Inc does not follow the US Stock Market performance with the rate: -22.7%.
Estimated limits based on current volatility of 6.0%: low 1.91$, high 2.13$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.25$, 4.49$]
- 2024-12-30 to 2025-12-30 estimated range: [1.49$, 4.86$]
Financial Metrics affecting the LIXT estimates:
- Negative: Non-GAAP EPS, $ of -2.70 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -49.52 <= 2.35
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term LIXT quotes
Long-term LIXT plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
Operating Expenses | $6.72MM | $6.31MM | $5.09MM |
Operating Income | $-6.72MM | $-6.31MM | $-5.09MM |
Non-Operating Income | $-0.01MM | $-0.00MM | $0.00MM |
Interest Expense | $0.01MM | $0.01MM | $0.00MM |
R&D Expense | $1.74MM | $1.35MM | $0.90MM |
Income(Loss) | $-6.73MM | $-6.31MM | $-5.09MM |
Profit(Loss) | $-6.73MM | $-6.31MM | $-5.09MM |
Stockholders Equity | $4.79MM | $5.17MM | $3.99MM |
Assets | $5.09MM | $5.56MM | $4.31MM |
Operating Cash Flow | $-4.14MM | $-4.61MM | $-4.29MM |
Financing Cash Flow | $3.90MM | $5.14MM | $3.14MM |
Earnings Per Share* | $-5.00 | $-39.85 | $-2.66 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.